Dipal Doshi, the CEO of Entrada Therapeutics, has an impressive background in the biopharmaceutical field. He earned his MBA from Harvard Business School, which gives him a solid foundation in business leadership. Since taking the helm at Entrada in March...

Dipal Doshi, the CEO of Entrada Therapeutics, has an impressive background in the biopharmaceutical field. He earned his MBA from Harvard Business School, which gives him a solid foundation in business leadership. Since taking the helm at Entrada in March 2021, he has steered the company through critical phases of growth and development. In 2022, his annual compensation exceeded $3.49 million, showcasing his pivotal role in the company's success and his contributions to its strategic direction. Mr. Doshi’s deep involvement in decision-making has significantly affected Entrada's trajectory. Notably, his total compensation has seen a steady growth, rising from around $554,000 in 2021 to nearly $1 million the next year. During his tenure, Doshi has been actively involved in stock trading, making significant transactions that reflect his confidence in the company's future, such as selling stocks worth over $3 million at various times. His hands-on approach and financial acumen demonstrate a keen understanding of both the market and the needs of the company.